The mission of the Center for Advancement of Blood Cancer Therapies (CABCT) is to accelerate the development of new therapies for blood cancers and other blood diseases.
Our goal is to advance new therapies through basic research leading to discoveries of new disease mechanisms and new therapeutic targets, along with preclinical and clinical research to translate these discoveries to the clinic. To this end, we bring together basic, translational, and clinical researchers with a commitment to the investigation of human disease. We seek to identify new areas of synergy and foster interactions that lead to translation of new discoveries to new therapies, including conventional drugs and cell therapies. CABCT is supported and co-sponsored by the Institute for Regenerative Medicine and The Tisch Cancer Institute.